Sen. Charles E. Grassley, R-Iowa, chairman of the Senate Finance Committee, is questioning Northfield Laboratories' and the FDA's actions regarding a 720-patient trauma study of a blood substitute. Grassley is looking into whether patients were aware of potential side effects and the full results of a previous study on PolyHeme.

Related Summaries